Edward E Walsh1,2, Lu Wang3, Ann R Falsey1,2, Xing Qiu3, Anthony Corbett3, Jeanne Holden-Wiltse3, Thomas J Mariani4,5,6, David J Topham7, Mary T Caserta6. 1. Department of Medicine, University of Rochester School of Medicine. 2. Department of Medicine, Rochester General Hospital, Rochester, New York. 3. Department of Biostatistics and Computational Biology, University of Rochester School of Medicine. 4. Department of Neonatology, University of Rochester School of Medicine. 5. Program in Pediatric Molecular and Personalized Medicine, University of Rochester School of Medicine. 6. Department of Pediatrics, University of Rochester School of Medicine. 7. Department of Microbiology and Immunology, University of Rochester School of Medicine.
Abstract
Background: Maternally derived serum antibody and viral load are thought to influence disease severity in primary respiratory syncytial virus (RSV) infection. As part of the AsPIRES study of RSV pathogenesis, we correlated various serum antibody concentrations and viral load with disease severity. Methods: Serum neutralizing antibody titers and levels of immunoglobulin G (IgG) to RSV fusion protein (F), attachment proteins of RSV group A and B, the CX3C region of G, and nasal viral load were measured in 139 full-term previously healthy infants with primary RSV infection and correlated with illness severity. Results: Univariate analysis showed no relationship between measures of serum antibody and severity. However, a multivariate model adjusting for age at the time of infection found a significant 0.56 decrease in severity score for each 2-fold increase in antibody concentration to RSV F. The benefit of antibody was greatest in infants ≤ 2 months of age. Additionally, estimated antibody titer at birth was correlated with age at infection, suggesting that higher antibody titers delay infection. Viral load did not differ by illness severity. Conclusion: Our data support the concept of maternal immunization with an RSV vaccine during pregnancy as a strategy for reducing the burden of RSV infection in full-term healthy infants exposed to RSV during their first winter.
Background: Maternally derived serum antibody and viral load are thought to influence disease severity in primary respiratory syncytial virus (RSV) infection. As part of the AsPIRES study of RSV pathogenesis, we correlated various serum antibody concentrations and viral load with disease severity. Methods: Serum neutralizing antibody titers and levels of immunoglobulin G (IgG) to RSV fusion protein (F), attachment proteins of RSV group A and B, the CX3C region of G, and nasal viral load were measured in 139 full-term previously healthy infants with primary RSV infection and correlated with illness severity. Results: Univariate analysis showed no relationship between measures of serum antibody and severity. However, a multivariate model adjusting for age at the time of infection found a significant 0.56 decrease in severity score for each 2-fold increase in antibody concentration to RSV F. The benefit of antibody was greatest in infants ≤ 2 months of age. Additionally, estimated antibody titer at birth was correlated with age at infection, suggesting that higher antibody titers delay infection. Viral load did not differ by illness severity. Conclusion: Our data support the concept of maternal immunization with an RSV vaccine during pregnancy as a strategy for reducing the burden of RSV infection in full-term healthy infants exposed to RSV during their first winter.
Authors: Chadi M El Saleeby; Andy J Bush; Lisa M Harrison; Jody A Aitken; John P Devincenzo Journal: J Infect Dis Date: 2011-10-01 Impact factor: 5.226
Authors: S Boyoglu-Barnum; S O Todd; J Meng; T R Barnum; T Chirkova; L M Haynes; S J Jadhao; R A Tripp; A G Oomens; M L Moore; L J Anderson Journal: J Virol Date: 2017-04-28 Impact factor: 5.103
Authors: Jennifer Harcourt; Rene Alvarez; Les P Jones; Christine Henderson; Larry J Anderson; Ralph A Tripp Journal: J Immunol Date: 2006-02-01 Impact factor: 5.422
Authors: Edward E Walsh; Derick R Peterson; Aja E Kalkanoglu; Frances Eun-Hyung Lee; Ann R Falsey Journal: J Infect Dis Date: 2013-02-04 Impact factor: 5.226
Authors: Joyce Uchi Nyiro; Charles Jumba Sande; Martin Mutunga; Patience Kerubo Kiyuka; Patrick Kioo Munywoki; John Anthony G Scott; David James Nokes Journal: PLoS One Date: 2016-11-16 Impact factor: 3.240
Authors: Michael L Forbes; Veena R Kumar; Ram Yogev; Xionghua Wu; Gabriel J Robbie; Christopher S Ambrose Journal: Hum Vaccin Immunother Date: 2014 Impact factor: 3.452
Authors: David T Siefker; Luan Vu; Dahui You; Andrew McBride; Ryleigh Taylor; Tamekia L Jones; John DeVincenzo; Stephania A Cormier Journal: Am J Respir Crit Care Med Date: 2020-02-01 Impact factor: 21.405
Authors: Samadhan J Jadhao; Binh Ha; Courtney McCracken; Tebeb Gebretsadik; Christian Rosas-Salazar; James Chappell; Suman Das; Tina Hartert; Larry J Anderson Journal: J Med Virol Date: 2020-12-29 Impact factor: 20.693
Authors: Edward E Walsh; Thomas J Mariani; ChinYi Chu; Alex Grier; Steven R Gill; Xing Qiu; Lu Wang; Jeanne Holden-Wiltse; Anthony Corbett; Juilee Thakar; Matthew N McCall; David J Topham; Ann R Falsey; Mary T Caserta; Lauren Benoodt Journal: JMIR Res Protoc Date: 2019-06-06
Authors: Abhijeet R Sonawane; Liang Tian; Chin-Yi Chu; Xing Qiu; Lu Wang; Jeanne Holden-Wiltse; Alex Grier; Steven R Gill; Mary T Caserta; Ann R Falsey; David J Topham; Edward E Walsh; Thomas J Mariani; Scott T Weiss; Edwin K Silverman; Kimberly Glass; Yang-Yu Liu Journal: Sci Rep Date: 2019-09-25 Impact factor: 4.379
Authors: Diego R Hijano; Luan D Vu; Lawrence M Kauvar; Ralph A Tripp; Fernando P Polack; Stephania A Cormier Journal: Front Immunol Date: 2019-03-26 Impact factor: 7.561
Authors: Chin-Yi Chu; Xing Qiu; Matthew N McCall; Lu Wang; Anthony Corbett; Jeanne Holden-Wiltse; Christopher Slaunwhite; Alex Grier; Steven R Gill; Gloria S Pryhuber; Ann R Falsey; David J Topham; Mary T Caserta; Edward E Walsh; Thomas J Mariani Journal: J Infect Dis Date: 2021-05-20 Impact factor: 7.759